Literature DB >> 18076112

A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia.

Javier Pagonabarraga1, Gisela Llebaria, Carmen García-Sánchez, Berta Pascual-Sedano, Alexandre Gironell, Jaime Kulisevsky.   

Abstract

Delusional misidentification syndromes (DMS) are a group of neuropsychiatric disorders due to disturbances in familiarity. DMS in organic diseases have been related to deficits in executive, memory, and visuospatial function. DMS are frequently reported in dementia with Lewy bodies (DLB). The presence of DMS in Parkinson's disease with dementia (PDD), which shares similar clinical and neuropsychological features with DLB, has not been studied. We describe the frequency and clinical features of DMS in a cohort of PDD patients, and we compare the neuropsychological profile between PDD patients with and without DMS. Prospective study of 30 PDD patients recruited from an outpatient setting, who received a structured behavioral interview assessing DMS and hallucinations, and a neuropsychological battery assessing executive function, memory, language, and visuospatial abilities. DMS were found in 16.7% of PDD patients. All DMS subjects also exhibited hallucinations that were significantly more severe than in PDD without DMS. DMS were responsive to neuroleptic drugs. PDD subjects with DMS presented a different neuropsychological profile than PDD subjects without DMS, with more severe memory and language deficits, but similar levels of executive and visuospatial impairment. DMS is a neuropsychiatric feature associated with PDD. Greater impairment in language and memory in PDD with DMS suggests a prominent role of the temporal cortex in the genesis of DMS in PDD. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18076112     DOI: 10.1002/mds.21864

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

Review 1.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 2.  The spectrum of cognitive impairment in Lewy body diseases.

Authors:  Jennifer G Goldman; Caroline Williams-Gray; Roger A Barker; John E Duda; James E Galvin
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 3.  Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.

Authors:  Daniel Martinez-Ramirez; Michael S Okun; Michael S Jaffee
Journal:  Neurodegener Dis Manag       Date:  2016-07-13

4.  Treatment of psychosis and dementia in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden
Journal:  Curr Treat Options Neurol       Date:  2014-03       Impact factor: 3.598

Review 5.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

Review 6.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 7.  Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review.

Authors:  Rikinkumar S Patel; Jatminderpal Bhela; Muhammad Tahir; Sindhu Reddy Pisati; Sadaf Hossain
Journal:  Cureus       Date:  2019-07-28

Review 8.  Cognitive decline in Parkinson's disease: the complex picture.

Authors:  Roberta Biundo; Luca Weis; Angelo Antonini
Journal:  NPJ Parkinsons Dis       Date:  2016-09-01

9.  Incidence and lesions causative of delusional misidentification syndrome after stroke.

Authors:  Yasuro Kakegawa; Osamu Isono; Keisuke Hanada; Takashi Nishikawa
Journal:  Brain Behav       Date:  2020-09-07       Impact factor: 2.708

Review 10.  Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?

Authors:  Daniele Urso; Valentina Gnoni; Marco Filardi; Giancarlo Logroscino
Journal:  Front Psychiatry       Date:  2022-01-18       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.